NewAmsterdam Pharma Co N.V (NAMS) Operating Income: 2023-2025
Historic Operating Income for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Sep 2025 value amounting to -$55.1 million.
- NewAmsterdam Pharma Co N.V's Operating Income fell 120.55% to -$55.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$202.9 million, marking a year-over-year decrease of 10.21%. This contributed to the annual value of -$176.3 million for FY2024, which is 3.65% up from last year.
- Per NewAmsterdam Pharma Co N.V's latest filing, its Operating Income stood at -$55.1 million for Q3 2025, which was down 54.74% from -$35.6 million recorded in Q2 2025.
- In the past 5 years, NewAmsterdam Pharma Co N.V's Operating Income registered a high of -$25.0 million during Q3 2024, and its lowest value of -$68.9 million during Q1 2025.
- For the 3-year period, NewAmsterdam Pharma Co N.V's Operating Income averaged around -$47.2 million, with its median value being -$49.6 million (2023).
- Its Operating Income has fluctuated over the past 5 years, first soared by 49.55% in 2024, then tumbled by 120.55% in 2025.
- Quarterly analysis of 3 years shows NewAmsterdam Pharma Co N.V's Operating Income stood at -$51.1 million in 2023, then climbed by 15.36% to -$43.2 million in 2024, then plummeted by 120.55% to -$55.1 million in 2025.
- Its last three reported values are -$55.1 million in Q3 2025, -$35.6 million for Q2 2025, and -$68.9 million during Q1 2025.